The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
After receiving lamivudine for 3 years to treat chronic hepatitis B, 67–75% of patients develop B-domain L528M, C-domain M552I, or M552V mutations in the HBV polymerase that render hepatitis B virus (HBV) drug-resistant. The aim of this study was to evaluate the influence of these mutations on viral...
Gorde:
| Argitaratua izan da: | J Clin Invest |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society for Clinical Investigation
2001
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC199250/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11181644/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI11100 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|